The Amneal PATHways® Patient Support Program is designed to help patients and providers stay on course toward accessible treatment. With its full suite of services and dedicated Program Access Specialists, PATHways allows stakeholders to more easily map a patient’s personal treatment path together.
Eligible,* commercially insured patients may pay as little as $0 per treatment with an Amneal Biosciences product.
*Eligibility Criteria/Terms & Conditions: The Amneal PATHways Co-Pay Savings Program [Program] is NOT insurance. The Program is only available for residents of the US and Puerto Rico who have commercial health insurance with co-pay/co-insurance on each prescription fill per product. Uninsured and cash-pay individuals are NOT eligible for the Program nor are individuals with commercial insurance coverage that does not provide coverage for FOCINVEZ™ (fosaprepitant injection). Individuals with coverage for FOCINVEZ™ (fosaprepitant injection), in whole or in part, under any state or federally funded healthcare program, including but not limited to, Medicare, Medicare Advantage Plans, Medicare Part D (including Qualified Retiree Prescription Drug Plans), Medicaid, Medigap, VA, DoD, TRICARE, and the Puerto Rico Government Health Insurance Plan, are NOT eligible for the Program. Patients who move from commercial to state or federally funded insurance will no longer be eligible for the Program.
Patients may not combine this offer with any rebate, coupon, free trial, or similar offer. Patients must present a valid prescription for an eligible drug at a participating pharmacy. Federal and state laws and other factors may prevent or otherwise restrict eligibility. This offer is not valid where prohibited by law. Void if copied, transferred, purchased, altered, or traded. Amneal Pharmaceuticals LLC reserves the right to rescind, revoke or amend this offer or discontinue the Program at any time without notice.
When submitting claims under the Program, patients are certifying that they understand the Program rules, regulations and terms and conditions, and will comply with the Program terms as set forth herein. Additionally, you are certifying that a claim has not been submitted under a state or federally funded healthcare program, including but not limited to, Medicare, Medicare Advantage Plans, Medicare Part D (including Qualified Retiree Prescription Drug Plans), Medicaid, Medigap, VA, DoD, TRICARE, and the Puerto Rico Government Health Insurance Plan. Limit one Program enrollment per individual.
FOCINVEZ™ is a substance P/neurokinin-1 (NK1) receptor antagonist indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:
Limitations of Use:
FOCINVEZ™ has not been studied for the treatment of established nausea and vomiting.
To report SUSPECTED ADVERSE REACTIONS, contact Amneal Biosciences, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see accompanying full Prescribing Information.
FOCINVEZ™ is a substance P/neurokinin-1 (NK1) receptor antagonist indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:
+
